Questions About Cancer? 1-800-4-CANCER

Adult Non-Hodgkin Lymphoma Treatment (PDQ®)

Health Professional Version

Changes to This Summary (02/13/2015)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

General Information About Adult Non-Hodgkin Lymphoma (NHL)

Updated statistics with estimated new cases and deaths for 2015 (cited American Cancer Society as reference 2).

Indolent NHL

Added Dimopoulos et al. as reference 47 and Treon et al. as reference 48.

Aggressive NHL

Added text to state that patients with diffuse large B-cell lymphoma who are event-free after 2 years have a subsequent overall survival equivalent to that of the age- and sex-matched general population (cited Maurer et al. as reference 23).

Added text to state that according to an anecdotal prospective single-arm trial, describing a post-therapy–positive 18-fluorodeoxyglucose–positron-emission tomography as greater than liver uptake may identify patients with an increased risk of relapse (cited Martelli et al. as reference 41).

Added text to state that patients with breast implant–associated anaplastic large-cell lymphoma may do well without chemotherapy after capsulectomy and implant removal if the disease is confined to the fibrous capsule, and no associated mass is present (cited Miranda et al. as reference 57).

Revised text to state that anecdotal responses have been reported for cyclosporine, pralatrexate, bendamustine, the histone deacetylase inhibitor romidepsin, and brentuximab vedotin (cited Horwitz et al. as reference 86).

Revised text to state that anecdotal responses have been seen with pralatrexate, bendamustine, and brentuximab vedotin.

Added text to state that an indolent T-cell lymphoproliferative disease of the gastrointestinal tract must be distinguished from peripheral T-cell lymphoma because no therapy may be indicated (cited Perry et al. as reference 108).

Added Fenske et al. as reference 174.

Treatment for Indolent, Noncontiguous Stage II/III/IV Adult NHL

Added Flinn et al. as reference 30.

This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.

  • Updated: February 13, 2015